Research Analysts Offer Predictions for Eli Lilly and Company’s Q1 2024 Earnings (NYSE:LLY)

Eli Lilly and Company (NYSE:LLY – Get Rating) – Investment analysts at Jefferies Financial Group issued their Q1 2024 EPS estimates for shares of Eli Lilly and in a research note issued on Monday, March 6th. Jefferies Financial Group analyst A. Tewari forecasts that the company will earn $2.78 per share for the quarter. Jefferies Financial Group has a “Hold” rating and a $290.00 price objective on the stock. The consensus estimate for Eli Lilly and’s current full-year earnings is $8.48 per share. Jefferies Financial Group also issued estimates for Eli Lilly and’s Q3 2024 earnings at $2.63 EPS, Q4 2024 earnings at $2.71 EPS, FY2025 earnings at $14.73 EPS and FY2027 earnings at $20.15 EPS.

A number of other research firms also recently commented on LLY. Cowen raised their price objective on shares of Eli Lilly and from $390.00 to $430.00 in a report on Monday, December 5th. Guggenheim increased their target price on shares of Eli Lilly and from $399.00 to $401.00 and gave the stock a “buy” rating in a research report on Wednesday, December 7th. Societe Generale cut shares of Eli Lilly and from a “hold” rating to a “sell” rating and set a $278.00 target price for the company. in a research report on Wednesday, February 15th. Credit Suisse Group increased their target price on shares of Eli Lilly and from $395.00 to $400.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 6th. Finally, UBS Group dropped their target price on shares of Eli Lilly and from $428.00 to $420.00 and set a “buy” rating for the company in a research report on Thursday, December 15th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $373.57.

Eli Lilly and Price Performance

NYSE:LLY opened at $312.54 on Wednesday. The company has a 50-day moving average of $341.41 and a 200-day moving average of $341.00. The company has a market capitalization of $297.01 billion, a price-to-earnings ratio of 45.30, a PEG ratio of 1.82 and a beta of 0.36. Eli Lilly and has a 52 week low of $262.07 and a 52 week high of $384.44. The company has a debt-to-equity ratio of 1.37, a quick ratio of 0.80 and a current ratio of 1.05.

Eli Lilly and (NYSE:LLY – Get Rating) last released its quarterly earnings data on Thursday, February 2nd. The company reported $2.09 EPS for the quarter, topping analysts’ consensus estimates of $1.83 by $0.26. The company had revenue of $7.30 billion during the quarter, compared to the consensus estimate of $7.39 billion. Eli Lilly and had a net margin of 21.88% and a return on equity of 73.61%. The firm’s revenue for the quarter was down 8.7% compared to the same quarter last year. During the same period last year, the firm earned $2.49 EPS.

Eli Lilly and Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 10th. Shareholders of record on Wednesday, February 15th will be given a $1.13 dividend. This represents a $4.52 annualized dividend and a yield of 1.45%. The ex-dividend date is Tuesday, February 14th. This is a boost from Eli Lilly and’s previous quarterly dividend of $0.98. Eli Lilly and’s dividend payout ratio (DPR) is presently 65.51%.

Insider Buying and Selling at Eli Lilly and

In other news, EVP Anne E. White sold 2,500 shares of Eli Lilly and stock in a transaction that occurred on Monday, February 13th. The shares were sold at an average price of $346.47, for a total transaction of $866,175.00. Following the completion of the sale, the executive vice president now owns 57,926 shares in the company, valued at approximately $20,069,621.22. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 0.12% of the company’s stock.

Institutional Investors Weigh In On Eli Lilly and

Institutional investors have recently modified their holdings of the business. Insight Inv LLC acquired a new stake in shares of Eli Lilly and during the 2nd quarter worth approximately $26,000. Y.D. More Investments Ltd bought a new position in Eli Lilly and during the 4th quarter worth approximately $26,000. Destiny Wealth Partners LLC boosted its stake in Eli Lilly and by 97.8% during the 4th quarter. Destiny Wealth Partners LLC now owns 91 shares of the company’s stock worth $33,000 after acquiring an additional 45 shares during the last quarter. New Millennium Group LLC bought a new position in Eli Lilly and during the 2nd quarter worth approximately $34,000. Finally, Moisand Fitzgerald Tamayo LLC boosted its stake in Eli Lilly and by 292.6% during the 3rd quarter. Moisand Fitzgerald Tamayo LLC now owns 106 shares of the company’s stock worth $34,000 after acquiring an additional 79 shares during the last quarter. Institutional investors and hedge funds own 82.13% of the company’s stock.

About Eli Lilly and

(Get Rating)

Eli Lilly & Co engages in the discovery, development, manufacture and sale of pharmaceutical products. The firm’s products consist of Diabetes, Oncology, Immunology, Neuroscience, and Other therapies. The Diabetes products include Baqsimi, Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta, and Trulicity.